Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
"ABBVIE LIMITED, Clinician",Upadacitinib,Second line treatment of moderate to severe ulcerative colitis,Upadacitinib (RINVOQÂ®),,Community and Hospital,Alimentary Tract and Metabolism
